Abraham George R, Davenport Anthony P
Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Cell. 2023 Jan 19;186(2):240-242. doi: 10.1016/j.cell.2022.12.014. Epub 2023 Jan 4.
The potent vasoconstrictor peptide endothelin-1 has long been recognized as a physiological regulator of vascular tone. However, pharmacological blockade of the endothelin-1 pathway has few proven indications thus far. A recent clinical trial for resistant hypertension published in The Lancet may yet herald a new era for endothelin receptor antagonists into the clinical mainstream.
强效血管收缩肽内皮素-1长期以来一直被认为是血管张力的生理调节因子。然而，迄今为止，内皮素-1通路的药物阻断几乎没有已证实的适应症。最近发表在《柳叶刀》上的一项关于顽固性高血压的临床试验可能预示着内皮素受体拮抗剂进入临床主流的新时代。
